- Home
- TASK vs CDNA Comparison
TASK vs CDNA Comparison
Compare TASK & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TASK | CDNA |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.3M | 1.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TASK | CDNA |
|---|---|---|
| Price | $10.81 | $20.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $17.00 | ★ $26.67 |
| AVG Volume (30 Days) | 268.9K | ★ 777.2K |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | 0.88 | ★ 1.22 |
| Revenue | ★ $1,144,833,000.00 | $357,998,000.00 |
| Revenue This Year | $20.40 | $14.49 |
| Revenue Next Year | $7.35 | $11.32 |
| P/E Ratio | ★ $12.62 | $16.81 |
| Revenue Growth | ★ 19.88 | 14.46 |
| 52 Week Low | $10.58 | $10.96 |
| 52 Week High | $18.59 | $25.55 |
Technical Indicators
Market Signals| Indicator | TASK | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 54.98 |
| Support Level | $10.58 | $20.18 |
| Resistance Level | $11.66 | $21.20 |
| Average True Range (ATR) | 0.33 | 0.88 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 18.02 | 48.88 |
Price Performance
Historical ComparisonAbout TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.